Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKLMG6)

• Drug Name: KN035 Drug Info
• Synonyms: Envafolimab

Indication

Disease Entry	ICD 11	Status	REF
Pleomorphic sarcoma	2B54	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Advanced malignancy	2A00-2F9Z	Phase 1	[3]

• Cross-matching ID: TTD Drug ID: DMKLMG6

Molecule-Related Drug Atlas

Drug(s) Targeting Programmed cell death 1 ligand 1 (PD-L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avelumab	DMSZLJR	Merkel cell carcinoma	2C34	Approved	[4]
Durvalumab	DM4PVDY	Urothelial carcinoma	2C92.0	Approved	[5]
RG-7446	DM69XMQ	Urothelial carcinoma	2C92.0	Approved	[6]
Bavencio	DMU9C8F	Merkel cell carcinoma	2C34	Approved	[7]
Atezolizumab	DMMF8U0	Non-small-cell lung cancer	2C25	Approved	[8]
Sugemalimab	DMH5YQ3	Non-small-cell lung cancer	2C25	Approved in China	[9]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[10]
MEDI4736	DM5X849	Solid tumour/cancer	2A00-2F9Z	Phase 3	[11]
MPDL-3280A	DM9K3LM	Melanoma	2C30	Phase 3	[12]
CS1001	DMSY0NE	Non-small-cell lung cancer	2C25	Phase 3	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Not Available	[3]

References

• [1] ClinicalTrials.gov (NCT04480502) ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC). U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04891198) ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [3] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [4] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
• [7] ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [9] Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
• [10] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [11] National Cancer Institute Drug Dictionary (drug id 740856).
• [12] Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
• [13] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.